

1 **Systematic review and meta-analysis of COVID-19 vaccines safety, tolerability,**
2 **and efficacy among HIV-infected patients**

3 Jacques L Tamuzi¹, Ley M Muyaya¹, Amal Mitra², Peter S Nyasulu^{1,3*}

4 **Author affiliations**

5 ¹Division of Epidemiology, Faculty of Medicine and Health Sciences, Stellenbosch
6 University, Cape Town, South Africa

7 ²Department of Epidemiology and Biostatistics, School of Public Health, College of
8 Health Sciences, Jackson State University, Jackson, Mississippi, USA

9 ³Division of Epidemiology, School of Public Health, Faculty of Health Sciences,
10 University of the Witwatersrand, Johannesburg, South Africa

11

12

13 ****Corresponding author:** **Peter S. Nyasulu, Division of Epidemiology & Biostatistics,
14 Faculty of Medicine & Health Sciences, Stellenbosch University, Cape Town, South
15 Africa. Email: <pnyasulu@sun.ac.za>

16

17

18

19

20

21

22

23

24

25

26

27

28

29 **Abstract**

30 **Objective**

31 To conduct a comprehensive systematic review and meta-analysis of all recommended
32 SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) vaccines in people
33 living with HIV (PLWH), as well as an overview of the safety, tolerability, and efficacy of
34 the vaccines in PLWH.

35 **Methods**

36 We searched six databases, Cochrane Central Register of Controlled Trials
37 (CENTRAL), PubMed, Medline, Medrxiv, Global research on COVID-19 database, and
38 Google Scholar for studies investigating the effects of SARS-CoV-2 vaccines on PLWH.
39 Results of the association were summarised by SARS-CoV IgG seroconversion and
40 level, vaccines efficacy and tolerability. A meta-analysis was performed for studies,
41 using random-effects model and a pooled RR with 95% CI was reported.

42 **Results**

43 Twenty-three of the 1052 studies screened met the inclusion criteria. The review
44 included 28, 246 participants among whom 79.55% (22,469/28, 246) were PLWH with
45 median CD4 \geq 200 cells/ μ L. The pooled estimate of SARS-CoV-2 IgG seroconversion
46 and positive neutralizing antibodies after the second vaccination dose between PLWH
47 vs HIV negative were RR 0.95 (95%CI: 0.92 – 0.99, P = 0.006) and 0.88 (95%CI: 0.82-
48 0.95, P = 0.0007), respectively. The mean difference of IgG antibodies level (BAU/ml)
49 was found higher in mRNA vaccines MD -1444.97 (95%CI: -1871.39, -1018.55). PLWH
50 with CD4 less than 500 cells/ μ l had 15% risk reduction of neutralizing antibodies

51 response compared to those with CD4 \geq 500 cells/ μ l (P = 0.003). The SARS-CoV-2
52 vaccine effectiveness was 65% (95%CI: 56%-72%, P <0.001) among vaccinated
53 compared to unvaccinated PLWH. PLWH with CD4 count <350 cells/ μ l had lower
54 vaccine effectiveness compared to CD4 count \geq 350 cells/ μ l with 59% vs 72%,
55 respectively. Vaccine tolerability was the same between PLWH and HIV negatives.

56 **Conclusion**

57 According to our findings, PLWH with CD4 \geq 200 cells/ μ L had lower immunogenicity and
58 antigenicity in COVID-19 vaccines than HIV negatives. Additional doses of SARS-CoV-
59 2 vaccination are needful in PLWH.

60 Key words: SARS-CoV-2, COVID-19, vaccines, efficacy, tolerability, HIV, PLWH

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76 **1. Background**

77

78 Nearly 37.6 million [30.2 million–45.0 million] people worldwide are infected with Human
79 Immunodeficiency Virus (HIV) [1], with Sub-Saharan Africa accounting for nearly 71%
80 [2]. HIV and the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are
81 the main syndemics of the twenty-first century. A recent study of over 15,000 cases of
82 COVID-19 in people living with HIV carried out by WHO revealed that PLWH were 13%
83 more likely to be admitted to hospital with severe or critical COVID-19 after controlling
84 for age, gender, and comorbidities [3]. Furthermore, PLWH were more likely to die after
85 admission to hospital with COVID-19 with a 30% increased risk of death independent of
86 age, gender, severity at presentation, and co-morbidities [3] and diabetes, high blood
87 pressure, male sex, or over 75 years old were each associated with an increased risk of
88 death [4]. Another study including 22 studies and 20,982,498 participants revealed that
89 PLWH had a significantly higher risk of SARS-CoV-2 infection than HIV-negative
90 individuals [5]. These multi-morbidities are driven by residual inflammation on ART and
91 ongoing immune dysregulation [6] that could influence COVID-19 disease severity, the
92 durability of protective antiviral responses, and responsiveness to vaccination [7-9].
93 Cellular immune deficiency and a low current or nadir CD4 cell count have been
94 identified as potential risk factors for severe SARS-CoV-2 infection in PLWH,
95 irrespective of HIV virological suppression [10]. Conversely, persistent inflammation or
96 lower CD4-to-CD8 cell ratios among PLWH than among those without HIV could
97 increase susceptibility to viral infection [11, 12]. With emerging information on PLWH
98 with COVID-19 disease, a more pronounced immunodeficiency, defined as a current
99 CD4 count <350/ μ L and a low CD4 nadir, has been associated with an increased risk

100 for severe COVID-19 and mortality [7]. Furthermore, HIV infection is associated with
101 chronic inflammation and immune activation, which can accelerate the aging process of
102 the immune system, rendering it less responsive [13]. With daily antiretroviral therapy
103 (ART), significant immune dysfunction in PLWH can be reversed and prevented [14-16].
104 Successful ART results in undetectable plasma HIV viraemia and a return to normal
105 CD4+ T cell counts [16, 17]. Despite ART, HIV-associated immune pathology is not
106 completely reversed, and many patients experience persistent T cell activation and
107 exhaustion for years [10, 16, 18, 19]. It is therefore likely that HIV-1 infection impairs the
108 SARS-CoV-2 immune response [20].

109 Despite limited data, available information suggests current WHO-recommended
110 COVID-19 vaccines are safe for people living with HIV [21]. Several SARS-CoV-2
111 vaccines have proved safe and efficacious in large clinical trials, and studies are
112 ongoing to fully characterize their safety, tolerability, immunogenicity, and efficacy.
113 Although there are limited data in people with PLWH, mRNA, adenovirus-vectored DNA,
114 subunit (protein), and inactivated vaccines raise no safety concerns that are specific to
115 people with HIV [22]. Apart from this, the event of SARS-CoV-2 vaccination programs
116 need emphasizes in PLWH. The existing data are still controversial, and gaps remain
117 about the SARS-CoV-2 vaccines efficacy, safety, and tolerability in PLWH. Therefore,
118 there is an urgent need to conduct a comprehensive systematic review and meta-
119 analysis that include all vaccination against SARS-CoV-2 in PLWH and provide an
120 overview of safety, tolerability, and efficacy, describe the immune responses of SARS-
121 CoV-2 vaccines in PLWH. Such knowledge is critical for future COVID-19 prevention in

122 PLWH during the pandemic, as well as informing vaccination strategies in this specific
123 group.

124

125 **2. Methods**

126

127 **2.1 Overview**

128

129 This study followed the Preferred Reporting Items for Systematic Reviews and Meta-
130 Analyses (PRISMA) guidelines [23]. The review protocol was registered in the
131 International Prospective Register of Systematic Reviews (review registration number:
132 CRD42021228863) [24].

133 **2.2 Eligibility criteria**

134

135 Randomized trials, open-label and non-randomized, cohort study, case-control study,
136 and a cross-sectional study comparing different SARS-CoV-2 vaccines among which
137 nucleic acid vaccines among (mRNA, DNA vaccines, and other popular vaccine forms),
138 vector vaccines, inactivated vaccines, and live-attenuated vaccines between PLWH and
139 HIV negative people, or between PLWH with different CD4 count and/or interventions.
140 We included adults ≥ 18 years of age with HIV, with or without a history of SARS-CoV-2
141 infection. All the participants included in the intervention group had proof of approved
142 PLWH on highly active antiretroviral therapy (HAART). Additionally, PLWH with a
143 history of SARS-CoV-2 infection was confirmed by a previous SARS-CoV-2 PCR. The
144 non-intervention group included HIV-negative subjects and/or HIV-infected (not

145 vaccinated or vaccinated with different SARS-CoV-2 vaccines, different from the
146 intervention group).

147

148

149

150 **2.3. Electronic searches**

151

152 We searched eligible studies including SARS-CoV-2 vaccines in PLWH, published in
153 English from January 2020 to November 2021 in different databases, Cochrane Central
154 Register of Controlled Trials (CENTRAL), PubMed, Medline, Medrxiv
155 (<https://www.medrxiv.org>), Global research on COVID-19 database
156 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov>) and Google Scholar. We also searched studies on
157 Medical Literature Analysis and Retrieval System Online, WHO International Clinical
158 Trials Registry Platform (<http://www.who.int/ictrp/en/>), Global Alliance for Vaccine and
159 Immunisation, Coronavirus Clinical Studies or COVID-19 Prevention Network
160 (<https://www.coronaviruspreventionnetwork.org/>), ClinicalTrials.gov
161 (<https://www.ClinicalTrials.gov/>), Conference on Retroviruses and Opportunistic
162 Infections(CROI), HIV i-base website and International AIDS Society (IAS).

164 The following search strategy was conducted in PUBMED and MEDLINE: "COVID-
165 19"[Mesh:NoExp]) OR "SARS-CoV-2"[Majr:NoExp]) AND "HIV"[Mesh]) OR
166 "Immunosuppression"[Majr]) OR "Immunocompromised Host"[Majr]) AND
167 "Vaccines"[Majr])) OR "Vaccination"[Mesh]) OR "Immunization"[Majr]) OR

168 "Immunogenicity, Vaccine"[Majr]) AND "Safety"[Majr:NoExp]) OR "Treatment
169 Outcome"[Majr]. The following keywords were used to search studies on other
170 databases and conference websites: "COVID-19 vaccines, SARS-CoV-2 vaccines, HIV,
171 HIV-infected patients, immune-depression, immunocompromised, efficacy, and
172 tolerability". (SARS-CoV-2 vaccines OR COVID-19 vaccines) and (HIV-infected people
173 OR HIV OR immunocompromised OR immunosuppression) and (SARS-CoV-2-specific
174 antibodies OR SARS-CoV-2 spike antibody responses).

175 **2.4. Study selection**

176
177 Duplicate studies were deleted electronically using EndNote's "Find Duplicates" tool,
178 and all studies collected from electronic databases using the search method were
179 imported into EndNote V.X9.5. The studies were manually reviewed again to identify
180 and remove any additional duplicates. Two authors (JLT and LMM) choose papers that
181 are unrelated to one another. For any titles and abstracts that appear to fit the inclusion
182 requirements or where there is any doubt, complete articles were collected.
183 Inappropriate population, improper intervention, improper comparison, inappropriate
184 outcome(s), inappropriate study design, and others were excluded. Following selection,
185 the two authors (JLT and LMM) discussed their choices and reached an agreement on
186 any disparities. If JLT and LMM authors were unable to achieve an agreement, PSN
187 was consulted. Cohen's kappa (κ) statistics were used to calculate the overall
188 agreement rate before discrepant items are corrected. Following the resolution of
189 conflicts, the overall precision of searches was calculated by dividing the number of
190 studies included by the total number of studies screened after duplicates were removed.
191 The degree of agreement between the two independent data extractors (JLT and LMM)

192 was computed using kappa statistics to indicate the difference between observed and
193 expected agreements at random or by chance only. The following was how the Kappa
194 values were interpreted: (1) less than 0 equals less than chance agreement, (2) 0.01–
195 0.20: small agreement, (3) 0.21–0.40: good agreement, (4) 0.41–0.60: moderate
196 agreement, (5) 0.61–0.80: significant agreement, and (6) 0.8–0.99: practically perfect
197 agreement [25].

198

199

200 **2.5. Quality assessment**

201

202 Two reviewers (JLT and LMM) independently assessed the risk of bias in the included
203 papers. Any disagreement between the two reviewers about the risk of bias was settled
204 by a conversation with the third reviewer (PSN). For randomized controlled trials, the
205 Cochrane risk bias assessment tool was used [26]. Random sequence creation,
206 concealment of allocations, blinding of participants and staff, blinding of outcome
207 assessments, insufficient data on outcomes, and selective reporting were all part of the
208 risk assessment [26]. A bias risk assessment tool in non-randomized intervention
209 studies (ROBINS-I) was used to assess the risk of bias in included non-randomized
210 studies, including bias due to confounding (pre-intervention), bias in the selection of
211 study participants (pre-intervention), and bias in the classification of interventions
212 (intervention), bias due to deviations from the intended intervention (post-intervention),
213 bias due to missing data (post-intervention), bias in the measurement of outcomes
214 (post-intervention), bias in the selection of reported outcomes (post-intervention) and

215 overall bias risk [27]. We assessed the risk of bias as the low, moderate, serious, critical
216 risk of bias, and no information [27].

217

218 **2.6. Data abstraction**

219

220 Data were extracted by two independent reviewers (JLT and LMM) using a
221 standardized data abstraction form, developed according to the sequence of variables
222 required from the primary studies. Disagreements in data abstraction between the
223 reviewers were resolved by a third independent reviewer (PSN). All data were extracted
224 into an Excel worksheet template. Data were extracted on the following: author's first
225 name, publication date and location (country in which the research was conducted),
226 methods (study design, study setting, sample size, total study duration, withdrawal, and
227 date of study), participants (sample size, gender, mean age, median and ranges CD4
228 count, HIV viral load (suppressed or not suppressed), inclusion and exclusion criteria),
229 interventions (COVID-19 nucleic acid vaccines, vector vaccines, inactivated vaccines
230 and live attenuated vaccines), and comparisons included PLWH with placebo, no
231 intervention or different vaccines compared to the intervention group. We also included
232 as comparisons HIV-negative with placebo, no intervention, and same vaccine as the
233 intervention group.

234 The primary and secondary outcomes were specified and collected, and time points
235 were reported. We included primary outcomes among which seroconversion for SARS-
236 CoV-2 neutralizing antibody after the first and the second doses of the vaccines, IgG
237 antibody level after the first and second vaccines doses, anti-SARS-CoV-2 neutralizing
238 antibodies, SARS-CoV-2 vaccines effectiveness, local and systematic reactions after

239 the first and second doses. The second outcomes included PLWH subgroups based on
240 CD4 count < 200 vs ≥ 200 cells/ μ l; <350 vs ≥ 350 cells/ μ l; and <500 vs ≥ 500 cells/ μ l.

241

242 **2.7. Interventions**

243

244 The interventions included any type of SARS-CoV-2 vaccine regardless of dose (1, 2, or
245 3 doses), administration routes, and duration. Based on the mechanism of action of
246 SARS-CoV-2 vaccines, we grouped them as inactivated or weakened virus vaccines,
247 protein-based vaccines, viral vector vaccines, RNA and DNA vaccines administered as
248 primary series of one or two doses according to vaccines protocols.

249 **Inactivated vaccines:** Are kind of whole-cell vaccine in which the pathogenic materials
250 of the causing pathogen or a very similar one are destroyed by chemicals (such as
251 formaldehyde or beta-propiolactone), radiation, or heat. This demolishes the pathogen's
252 ability to replicate while keeping its immunization potential [28, 29]. One of the
253 inactivated vaccines manufactured for the COVID-19 infection is CoronaVac® or
254 Sinovac® containing the inactivated virus and aluminium as an adjuvant.

255 **Protein subunit vaccines:** Subunit vaccines merely consist of the immunogenic
256 proteins derived from a pathogen, which can stimulate the host's immune system [29].
257 The proteins can be easily produced by recombinant DNA techniques [29, 30]. It was
258 shown that protein subunit vaccines together with adjuvants generated a potent
259 response against SARS-CoV-2 [29]. The vaccines have good safety profiles since there
260 are no live components; reactogenicity and side effects are mainly related to adjuvants
261 [31]. In the case of Novavax, neutralizing antibodies (nAbs) was 100-times higher after

262 the second dose and 4-times higher than symptomatic outpatients after 35 days [29,
263 32].

264 **Viral vector vaccines:** A viral vector is a modified virus used to deliver a target gene to
265 the host cell. Modified virus is obtained by inserting an immunogenic part of the desired
266 virus, which is the S protein gene for SARS-CoV2 into a safe and non-pathogenic virus
267 as a vector [29, 33]. Subunit Vaccines targets are S proteins in the development of
268 subunit vaccines, which would lead to inhibition of the binding of the viruses to the host
269 angiotensin-converting enzyme 2 (ACE2) [34, 35]. There are two types of viral vector
270 vaccines: non-replicating and replicating. The non-replicating vectors do not have genes
271 responsible for replication, so they cannot replicate and only produce virus antigens. On
272 the other hand, replicating vectors, multiply in the body and infect other cells, causing all
273 cells to produce antigens [36, 37]. Viral vector vaccines include ChAdOx1 nCoV-
274 19, Sputnik V, Ad26.COV2-S, Ad5-nCoV, and others.

275 **Nucleic Acid Vaccines:** are usually made of mRNA molecules encapsulated in lipid
276 nanoparticles (LNP). LNP facilitates mRNA penetration into the host cell so that the
277 translation process can be initiated [28, 29]. The cellular immune response is seen
278 when the S proteins are presented to immune cells either by the MHC class I or II
279 complex, activating both CD4⁺ and CD8⁺ cells [29]. The salient features of mRNA
280 vaccines are: (i) Translation of mRNA occurs in the cytoplasm to avoid the risk of any
281 genome integration. (ii) Both T cell and antibody responses are triggered. (iii) Rapid
282 development and large-scale mass production can be achieved [31]. Two important
283 mRNA vaccines for COVID-19 are mRNA-1273 by Moderna TX, Inc, BNT162b1 by
284 BioNTech- Fosun Pharma-Pfizer, and LNP-nCoVsa RNA. A DNA vaccine is another

285 type of nucleic acid vaccine. DNA vaccines are produced by inserting the gene of an
286 antigenic protein into a bacteria-derived plasmid and delivering it to the host cells. The
287 protein-producing machinery of the host cell will translate DNA to mRNA and finally, a
288 protein that can stimulate the immune system.

289 **2.8. Outcomes**

290

291 2.8.1. Primary outcomes

292

293 **IgG antibody seroconversion for SARS-CoV-2 after the first and the second doses**
294 **of the vaccines:** defined as numbers or proportions of IgG seropositivity status such as
295 ELISA specific SARS-CoV-2 spike receptor-binding domain (RBD) antibody responses
296 among PLWH and HIV negatives.

297 **IgG antibody level after the first and second doses:** measured total binding
298 antibodies against SARS-CoV-2 nucleocapsid (N) and spike receptor-binding domain
299 (RBD). Results reported in arbitrary units (AU)/mL were converted to binding antibody
300 units (BAU/ml).

301 **SARS-CoV-2 neutralizing antibodies (NAbs) after the second vaccine dose:**
302 Antibodies that bind to Spike, a large homotrimeric glycoprotein studded across the viral
303 surface, have been shown to neutralize SARS-CoV-2 [35, 36]. NAbs are critical for virus
304 clearance and SARS-CoV-2 protection [37]. This outcome included numbers and
305 proportions of PLWH vs HIV negatives with high titers of neutralizing anti-S antibodies.

306 **SARS-CoV-2 vaccine efficacy (%)** was defined as $(1 - \text{Relative Ratio}) \times 100$, where RR
307 is the relative risk of Covid-19 illness including mild, moderate, severe, and critical

308 cases confirmed by Polymerase chain reaction (PCR) among vaccinated and
309 unvaccinated PLWH.

310 **Local and systematic reactions after the first and second doses:** Numbers and
311 proportions of PLWH vs HIV negatives with local and systemic AEs.

312 2.8.2. Secondary outcomes

313 The outcomes included PLWH subgroups based on positive neutralizing antibodies with
314 CD4 count < 200 vs ≥ 200 cells/ μl and <500 vs ≥ 500 cells/ μl : and vaccines effectiveness
315 <350 vs ≥ 350 cells/ μl . We also compared IgG antibody levels between different types of
316 vaccines.

317

318 2.9. Statistical analysis

319

320 The meta-analysis was carried out with the review manager software (Revman version
321 5.3) [38] and complementary analyses were undertaken with ProMeta version 3 [39].
322 We presented data from eligible studies in evidence tables and figures (map, flow
323 diagram, forest plots, funnel plot, and meta-regression figures). The relative risks (RR)
324 with 95% CI of the effect size for binary outcomes and the mean difference (MD) with
325 95% CI were reported for continuous outcomes. In cases where continuous outcomes
326 were reported in median (IQR), the conversion to mean (SE) was undertaken according
327 to [40]. We converted AU/ml to BAU/ml with the conversion factor as follows: 1 BAU/mL
328 = $0.142 \times \text{AU/mL}$. Pooled results from continuous outcomes have been expressed in
329 BAU/mL [41].

330 Based on the type of SARS-CoV-2 vaccines (viral vector, protein subunit, mRNA, DNA,
331 and inactivated vaccines), we built different forest plots including subgroup analysis of
332 vaccines type for the following outcomes: RBD IgG seroconversion, IgG antibody level,
333 neutralization antibodies responses, vaccine efficacy, SARS-CoV-2 post-vaccination,
334 local reaction, and systemic reactions. As statistical heterogeneity was significant
335 because of different vaccines groups, the random-effect model (Mantel-Haenszel or
336 inverse variance methods) was adopted in this meta-analysis. Heterogeneity between
337 the results of the primary studies was assessed using Cochran's Q test and quantified
338 with the I-squared statistic. A probability value less than 0.1 ($p < 0.1$) was considered to
339 suggest statistically significant heterogeneity [42]. Heterogeneity was considered low,
340 moderate, and high when the values are $< 25\%$, 25% to 75% , and $> 75\%$, respectively
341 [42]. In case of high heterogeneity (above 90%) after subgroup analysis, the results
342 were reported by type of vaccines or individual studies.

343 We computed Egger's regression and Begg Mazumdar's rank correlation test to
344 evaluate possible publication bias. We conducted a sensitivity analysis to assess the
345 robustness of our pooled RR of RBD antibody responses after the first and the second
346 dose of SARS-CoV-2 vaccines among PLWH and HIV-negative people. The quality of
347 evidence was assessed for each study using Grading of Recommendations,
348 Assessment, Development and Evaluation (GRADE) criteria [43]. The Grade was
349 assessed through the study design and risk of bias, inconsistency, indirectness,
350 imprecision, and publication bias [43].

351 **3. Results**

352

353 **3.1. Characteristics of included studies**

354
355 A total of 1122 studies were identified in the databases, of which 70 were eliminated as
356 duplicates, 1052 by reading titles and abstracts, 65 by reading the full text, and 42 were
357 excluded with reasons as mentioned in **Figure 1**. Twenty-three studies were selected
358 for the analysis [16, 44-65]. The review included 28, 246 participants among whom
359 79.55% (22,469/28, 246) were PLWH. All studies included participants 18 years and
360 above. All the medians' CD4 count was ≥ 200 cells/ μ l (Supplementary material: Table 1).
361 Sixteen studies reported the HIV viral load, among them, six studies included PLWH
362 with viral load < 50 copies/ml [16, 45, 49, 51, 53, 54] and nine other studies included
363 PLWH with viral load 58.1 to 95% suppressed [44, 46, 52, 55, 56, 58, 60, 61, 63, 65]
364 **(Supplementary material: Table 1)**.

365 The selected articles reported data from United States of America (n = 4) [48-50, 55],
366 China (n=5) [52, 54, 59, 61, 64], South Africa (n = 3) [45, 46, 57], United Kingdom (n =
367 2) [16, 53], Canada (n=2) [47, 51], Italia (n=1) [58], Brazil (n =1) [56], Germany (n =1)
368 [60], Israel (n = 1) [44], Sweden (n=1) [64], Taiwan (n=1) [65] and Russia (n = 1) [62]
369 **(Figure 2)**. Ten studies used randomized control designs [16, 45, 46, 49, 50, 53, 54, 64,
370 64, 65], eight studies used prospective cohort designs [44, 47, 48, 51, 52, 56-58], two
371 retrospective cohort studies [62, 63], two cross sectional studies [59, 61] and one case
372 control study [55] **(Supplementary material: Table 1)**. Eleven studies included mRNA
373 vaccines among which BNT162b2 mRNA, Vaccine, mRNA-1273 (100 μ g) administered
374 intramuscularly (IM) as a series of two doses (0.5 mL each), given 28 days apart [44,
375 47, 48, 50, 51, 53, 55, 58, 60, 63, 64], six studies included inactivated vaccines
376 including CoronaVac (3 μ g/0.5 mL), BBIBP-CorV (4 μ g/0.5 mL) or Sinovac (0.5 ml)

377 given intramuscularly [52, 54, 56, 59, 61, 64], seven studies included viral vector
378 vaccines among which ChAdOx1 nCoV-19 with two doses (5×10^{10} vp) was given 4-6
379 weeks apart, Ad26.COV2.S [16, 45, 49, 51, 57, 62, 63] and two study included sub unit
380 protein vaccine NVX-CoV2373 (5 μ g (sub unit) of recombinant spike protein with 50 μ g
381 of Matrix-M1 adjuvant) administered two intramuscular injections, 21 days apart and two
382 standard doses of 15 mcg MVC-COV1901, administered 28 days apart via IM injection
383 [46, 65] (**Supplementary material: Table 1**)

384 In terms of the bias risk analysis of the domains considered in the Cochrane
385 Collaboration tool [25], all eight randomized control trials [16, 45, 46, 49, 50, 63-65]
386 showed an unclear for allocation concealment bias risk (**Supplementary material:**
387 **Table 2**). Four papers reported a high risk of bias for random sequence generation as
388 well as masking of participants and professionals [16, 63-65], five trials showed a low
389 risk of blinding of participants and personnel [45, 46, 49, 50, 65], one study reported a
390 high risk of blinding of outcomes assessment [63], two studies reported a low risk of
391 other bias [49, 50], and others reported a high risk. In other domains, all studies
392 presented low bias risks (**Supplementary material: Table 2**). Regarding the risk of bias
393 of non-randomized studies, sixteen studies were assessed with the ROBINS-I bias tool
394 assessment [26]. Among them, seven were rated as low-moderate for the overall
395 ROBINS-I [44, 51, 52, 55, 57, 58, 60], four studies were low-serious [53, 54, 56, 62], one
396 study was moderate-serious [61], another study was Serious-Critical [48] and two
397 studies were critical [47, 59] (**Supplementary material: Table 3**).

398 **3.2. Meta-analysis**

399

400 **3.2.1. IgG seroconversion after 1st vaccination dose:**

401 **Figure 3** shows a comparative forest plot analysis of IgG seroconversion after the first
402 SARS-CoV-2 vaccines across published eight studies [16, 44, 45, 49, 52, 56] looking at
403 the RR between 935 PLWH with CD4 \geq 300 cells/ μ l and 1013 HIV negative people.
404 Overall, the random-effects model presented a RR of 0.83 (95%CI 0.65–1.06, 1948
405 participants, $P = 0.14$, $I^2 = 85\%$). The results presented by type of vaccine showed
406 SARS-CoV-2 inactivated vaccines administered in PLWH had 53% risk reduction of IgG
407 seroconversion compared to HIV negative people. In contrast mRNA and viral vaccines
408 did not have different seroconversion between PLWH and HIV negative people with RR
409 1.00(95%CI: 0.79-1.27) and 1.00(95%CI: 0.90-1.12), respectively.

410

411 **3.2.2. IgG seroconversion after 2nd vaccination dose:**

412 The pooled seroconversion results after SARS-CoV-2 vaccination second dose
413 between 1885 PLWH and 7768 HIV negative people showed statistically difference
414 between the two groups RR 0.95 (95%CI: 0.92 – 0.99, $P = 0.006$), with the test for
415 subgroup differences $I^2 = 41.3\%$ ($p = 0.16$) (**Figure 4**). IgG seroconversion after the
416 second vaccination dose was not statistically different between PLWH and HIV negative
417 people for mRNA and protein subunit vaccines with RR 0.98 (95%CI: 0.96-1.00, $P =$
418 0.06) and 0.91(95%CI: 0.42-1.98, $P = 0.81$), respectively. In contrast, viral vector and
419 inactivated vaccines reported statistically lower IgG seroconversion after second
420 vaccination dose

421 among PLWH with RR 0.93 (95%CI: 0.88-1.00, P = 0.04) and 0.90(0.81-0.99, P = 0.03),
422 respectively.

423

424 **3.2.3. IgG antibody level after the first dose of SARS-CoV-2 vaccines (BAU/ml)**

425

426 **Figure 5** reported IgG antibodies level after the first dose of SARS-CoV-2 vaccines. The
427 pooled result including eight studies [44, 45, 51-54, 56, 60] has shown that the mean
428 difference (MD) IgG antibody level (BAU/ml) did not differ between 643 PLWH and 762
429 HIV negatives after the first dose of SARS-CoV-2 vaccines MD-0.02 (95%CI: -0.09-
430 0.05, P = 0.58). The test of heterogeneity between studies was high ($I^2 = 83\%$).
431 However, the test for subgroup difference was not statistically significant ($I^2 = 33.6\%$, P
432 = 0.21).

433

434 **3.2.4. IgG antibody level (BAU/ml) after the second dose of SARS-CoV-2 vaccines**

435 Twelve studies reported IgG antibody levels after the second SARS-CoV-2 dose
436 (**Figure 6**). As heterogeneity was high between included studies and /or vaccines type,
437 the results were reported narratively. Eight studies out of eleven showed a statistically
438 significant decrease of the mean difference IgG antibody level after the second SARS-
439 CoV-2 dose (BAU/ml) among PLWH compared to HIV-negative people. The highest
440 and lowest statistically significant mean difference IgG antibody level (BAU/ml) after the
441 second SARS-CoV-2 dose were found in mRNA vaccines MD -1444.97 (95%CI: -
442 1871.39, -1018.55) [58] and MD -0.80(95%CI: -0.90, -0.70).

443 **3.2.5. SARS-CoV-2 vaccines effectiveness**

444 **Figure 7** described the RR of COVID-19 vaccines effectiveness among 20,314
445 vaccinated and unvaccinated PLWH. The pooled results included four studies [46, 49,
446 50, 62] showed that that vaccine effectiveness was 65% (95%CI: 56%-72%, $P < 0.001$)
447 among vaccinated compared to unvaccinated PLWH, with the test for subgroup
448 differences $I^2 = 0\%$ ($P = 0.47$).

449

450

451 **3.2.6. Vaccine's effectiveness based on CD4 count**

452

453 The pooled SARS-COV-2 vaccines effectiveness of 13,547 vaccinated and
454 unvaccinated PLWH with CD4 count < 350 vs ≥ 350 cells/ μ l was 69 % (95%CI: 58%-
455 78%, $P < 0.001$) (**Figure 8**). However, PLWH with CD4 count < 350 cells/ μ l had lower
456 vaccine effectiveness compared to CD4 count ≥ 350 cells/ μ l with 59% vs 72%,
457 respectively. The test for subgroup differences was not statistically different between the
458 two groups ($I^2 = 23.2\%$, $P = 0.25$) (**Figure 8**).

459

460

461

462 **3.2.7. SARS-CoV-2 vaccines neutralizing antibodies response after the second** 463 **dose**

464 **Figure 9** reported the pooled neutralizing antibodies response after the second dose of
465 SARS-CoV-2 vaccines between 769 PLWH and 613 HIV-negative people. PLWH had
466 12% risk reduction of neutralizing antibodies response compared to HIV negative
467 people with RR 0.88 (95%CI 0.82-0.95, 1,059 participants, $P = 0.0007$). mRNA vaccines
468 had statistically significant lower neutralizing antibodies response RR 0.89 (95%CI 0.84-
469 0.93, $P < 0.0001$). In contrast, neutralizing antibodies response between PLWH and HIV

470 negative people was not statistically significant with inactivated vaccines, RR 0.88
471 (95%CI 0.77-1.02, P = 0.10).

472

473 **3.2.8. Any local reaction after the first SARS-CoV-2 vaccines dose:**

474 The meta-analysis including five studies with local reactions after the first SARS-CoV-2
475 vaccines dose did not show statistically significant between PLWH and HIV negative
476 people with RR 0.98 (95%CI: 0.71 – 1.36, 1,688 participants, P = 0.91), with the test for
477 subgroup differences $I^2 = 80.9.0\%$ ($p = 0.001$). However, Levy and al. showed
478 significant local reactions among HIV negative people RR 1.59 (95%CI: 1.22-2.07, P =
479 0.0006) (**Figure 10**).

480

481 **3.2.9. Any systemic reaction after the first SARS-CoV-2 vaccines dose:**

482 Heterogeneity between protein subunit, mRNA, and the viral vector vaccines was high
483 in the meta-analysis of systemic reactions after the first SARS-CoV-2 vaccines dose,
484 therefore we reported the results separately. mRNA vaccine reported a lower risk of
485 systemic reactions after the first SARS-CoV-2 vaccine among PLWH compared HIV
486 negative people RR 0.41 (95%CI: 0.28 – 0.58). In contrast, both inactivated and viral
487 vector vaccines reported the same risk of systemic reaction after the first dose of SARS-
488 CoV-2 vaccines among PLWH and HIV-negative participants.

489

490 **3.2.10. Any local reaction after the second SARS-CoV-2 vaccines dose:**

491 The estimated RR of local reactions after the second SARS-CoV-2 vaccines dose
492 between 838 PLWH and 4, 533 HIV-negative people was not statistically different RR

493 0.97 (0.82 – 1.14, P = 0.06), with the test for subgroup differences $I^2 = 15.9\%$ (**Figure**
494 **12**).

495

496 **3.2.11. Any systemic reaction after the 2nd dose**

497 The pooled results of systemic reactions after the 2nd dose of SARS-CoV-2 vaccines
498 were not statistically significant between 591 PLWH and 942 HIV negative people RR
499 0.97 (95%CI: 0.82-1.14, P = 0.71) (**Figure 13**). In contrast, PLWH had less systemic
500 reaction after the second dose compared to HIV negative subjects' RR 0.69(95%: 0.53-
501 0.91, P = 0.009) (**Figure 13**).

502 **3.2.12. IgG seroconversion based on CD4 count (<500 vs ≥500** 503 **cells/μL) among PLWH**

504 The pooled result of IgG seroconversion based on CD4 count being less and above or
505 equal to 500 cells/ μL included 638 PLWH and five studies [47, 56-58, 61] (**Figure 14**).
506 The result revealed no statistically significant results between the two PLWH groups RR
507 (0.79, 95%CI: 0.63-1.00, P = 0.05) (**Figure 14**). Heterogeneity was high between the
508 vaccine types ($I^2 = 88$, P <0.001), however, the test for subgroup analysis was not
509 statistically significant between the vaccine groups ($I^2 = 24.2\%$, P = 0.27) (**Figure 14**).

510 **3.2.13. IgG seroconversion based on CD4 count (<200 vs ≥200** 511 **cells/μL) among PLWH**

512

513 **Figure 15** depicted the overall results of IgG seroconversion among 294 PLWH based
514 on CD4 count <200 or ≥200 cells/μL. The result did not show a statistically significant
515 difference between the two groups RR 0.68 (95%: 0.32-1.45, P = 32). The test for
516 subgroup analysis was not statistically different between the two groups ($I^2 = 61$, 6%, P
517 = 0.11).

518 **3.2.14. SARS-CoV-2 vaccines neutralizing antibodies response among**
519 **PLWH (<500 vs ≥500 cells/μL)**

520 The pooled result of neutralizing antibodies response of three studies [56, 58, 60]
521 revealed that PLWH with CD4 less than 500 cells/ μL had 15% risk reduction of
522 neutralizing antibodies response compared to those with CD4≥500 cells/μL (RR 0.85,
523 95%CI: 0.77-0.95, P = 0.003) (**Figure 16**).

524 **3.3. Sensitivity analysis**

525
526 To assess the robustness of our pooled RR of IgG seroconversion, IgG antibodies level,
527 neutralizing antibodies response, vaccine efficacy, local and systemic reactions after the
528 first and second dose of SARS-CoV-2 vaccines, we performed a sensitivity analysis.
529 This analysis revealed that the overall estimates of IgG seroconversion, IgG antibodies
530 level, neutralizing antibodies response, local and systemic reactions were robust and
531 were not influenced by a single study. However, the overall estimate of vaccine efficacy
532 was influenced by [62].

533

534 **3.4. Meta-regression**

535 Univariate meta-regression analyses were performed to investigate whether the median
536 age and CD4 count were associated with the SARS-CoV-2 IgG antibodies level effect
537 estimates. Twelve studies [16, 44, 45, 51-56, 58, 60, 61] reporting the median age of
538 CD4 count were included. Univariate meta-regression showed that neither the median
539 age nor CD4 cells/ μl were associated with the SARS-CoV-2 IgG antibodies level

540 (BAU/ml) effect estimates with the coefficient =0.15 and P= 0.739 (**Figure 17 a**) and
541 coefficient = -0.00 and P = 0.910 (**Figure 17b**), respectively.

542 **3.5. Publication bias**

543 As one of the pooled results included more than 10 studies, we built the funnel plot and
544 Egger's linear regression and Begg and Mazumdar's rank correlation tests were used to
545 assess publication bias. The symmetry of the funnel plots was examined to search for
546 possible publication bias or even heterogeneity. The funnel plot for IgG seroconversion
547 after the second dose of SARS-CoV-2 vaccines and IgG antibodies level were both
548 asymmetrical around a single peak (Figure 16). The result of Egger's test for small-
549 study effects showed that there was a statistically significant publication bias in
550 estimating IgG seroconversion after the second SARS-CoV-2 vaccination with Egger's
551 linear regression (t = -3.53 and P = 0.004) and Begg and Mazumdar's rank correlation
552 test, Z value for Kendall's tau = -1.53, p = 0.112. In the same, the Egger's linear
553 regression for IgG antibodies level (t = -3.34 and P = 0.007) and Begg and Mazumdar's
554 rank correlation test, Z value for Kendall's tau = -0.85, p = 0.393. This means that the
555 weighted regression test detected statistical evidence of bias.

556

557 **4. Discussion**

558

559 This systematic review and meta-analysis assessed SARS-CoV-2 vaccines' efficacy,
560 safety, and tolerability in PLWH. The review included twenty-three studies and 28, 246
561 participants among whom 79.55% (22, 469/28, 246) were PLWH. The studies included
562 adults with age ≥ 18 years. All studies included PLWH with median CD4 count ≥ 200
563 cells/ μ L. Sixteen out of twenty-three studies reported the HIV viral load. Among them,

564 six studies included PLWH with viral load < 50 copies/ml [16, 45, 49, 51, 53, 54] and ten
565 others included PLWH with viral load 58.1% to 95% suppressed [44, 46, 52, 55, 56, 58,
566 60, 61, 63, 65].

567 Our findings highlighted that PLWH had lower IgG seroconversion and neutralizing
568 antibodies response after the second vaccination dose compared to HIV negatives.
569 However, neutralizing IgG antibodies were not different between the two groups for
570 inactivated vaccines. The review also found that IgG antibody levels after the second
571 dose of SARS-CoV-2 vaccines were lower in PLWH as reported in 8 out of 12 studies.
572 However, three studies involving mRNA vaccines and heterogeneous (mRNA and viral
573 vector vaccines) showed statistically higher MD than viral vector and inactivated
574 vaccines [53, 58, 60]. Meta-regression revealed no relationship between the level of IgG
575 antibodies and the median CD4 count greater than 280 cells/L or age greater than 18
576 years. When compared to other SARS-CoV-2 vaccines, mRNA vaccines elicited a high
577 level of IgG antibodies [66]. By the way, mRNA vaccines produced higher levels of
578 antibodies after the second dose than the other vaccine groups. After the first dose of
579 SARS-CoV-2 vaccination, IgG antibody levels in PLWH and HIV-negative participants
580 were the same. This is significant because previous research has shown that SARS-
581 CoV-2 IgG seroconversion in PLWH was quickly lost, implying that PLWH were at a
582 disadvantage following COVID-19 vaccination [67]. According to a recent study, data
583 are currently insufficient to determine whether there is a significant decline in vaccine
584 effectiveness against any form of clinical illness caused by SARS-CoV-2 infection
585 beyond 6 months after vaccination [68]. According to Israeli data, approximately 40% of
586 breakthrough infections occur in immunocompromised individuals [68].

587 Our study also revealed that IgG seroconversions between <500 vs ≥ 500 cells/ μ l or
588 <200 vs ≥ 200 cells/ μ l were not different among PLWH. However, the neutralizing
589 antibodies response was lower in PLWH with CD4 count <500 cells/ μ l than ≥ 500
590 cells/ μ l. This should be taken in the context of a small sample size and missing data to
591 assess the impact of lower CD4 counts (< 200 and <500 cells/ μ L) on SARS-CoV-2
592 vaccines immunogenicity and antigenicity in PLWH. It should be noted that our included
593 studies had the median CD4 > 200 cells/ μ l. Based on low immunogenicity and
594 antigenicity among PLWH and knowing that severe immunosuppression due to
595 HIV/AIDS is defined as a current CD4 count of <200 cells/ μ l for adults or children [22].
596 Besides, the effectiveness of the SARS-CoV-2 vaccine was 65% between vaccinated
597 and unvaccinated PLWH. In the same, the SARS-CoV-2 among PLWH with CD4 count
598 ≥ 350 cells/ μ l was higher than those with CD4 count < 350 cells/ μ l. Our results may not
599 be generalizable to PLWH with CD4+ T-cell counts <200 cells/ μ l as the sample size
600 was very small in this specific subgroup and the vaccine effectiveness outcome was
601 highly influenced by one study including vector viral adenovirus vaccine [62]. Besides,
602 non-replicating vaccines, including those licensed for SARS-CoV-2 can be given to all
603 PLWH, although replicating vaccines should be avoided in those with CD4 count < 200
604 cells/ μ l [16, 49].

605 Currently, CDC is recommending that moderately to severely immunocompromised
606 people receive an additional dose [69]. The U.S Food and Drug Administration also
607 authorized the use of an additional dose of COVID-19 vaccines in people who are
608 immunocompromised [70, 71], reporting that a booster dose would provide enhanced
609 protection against COVID-19 in PLWH. The new recommendations are only about a

610 third dose to increase the level of protection from COVID-19 for PLWH with CD4 count
611 < 200 cells/ μ l [72]. As a general consideration, PLWH with CD4 counts <200 cells/ μ l
612 who are not on ART should first receive ART before vaccination [73]. Vaccination
613 should be deferred until a clinically significant immune reconstitution has been
614 achieved, preferentially after the CD4 cell count has increased >200 cells/mm³ [73]. In
615 fact, there are several reasons why COVID-19 vaccine booster doses may be needed in
616 PLWH: (i) waning protection against infection or disease, in particular severe disease,
617 over time (i.e., waning immunity), (ii) reduced protection against a variant(s) of concern
618 (VOC), or (iii) inadequate protection from the currently recommended primary series for
619 some risk groups for which evidence from long term SARS-CoV-2 IgG seroconversion
620 is lacking [73]. Additionally, evidence shows PLWH with a low CD4 count, high HIV viral
621 loads, and lack of ART use respond less strongly to vaccination, which is why they may
622 be offered a third dose [22]. In the same line, vaccination responses for PLWH may also
623 be suboptimal despite ART, and the duration of seroprotection was shorter in PLWH
624 [74-76], necessitating adjusted vaccine schedules or a booster [16, 77]. However, the
625 rationale for booster doses may differ by vaccine product, epidemiological setting, risk
626 group, and vaccine coverage rates [73]. According to a recent study, PLWH with well-
627 controlled viral loads on antiretroviral therapy and CD4+ T-cell counts in the healthy
628 range may not need a third COVID-19 vaccine dose as part of their initial immunization
629 series, though other factors such as older age, co-morbidities, vaccine regimen type,
630 and vaccine response durability will influence when this group may benefit from
631 additional doses [51]. Further, ART should be initiated as soon as possible, not only to
632 preserve immune function and avoid secondary HIV transmission but also to avoid the

633 complicated interaction between HIV infection and the above factors [78, 79]. While
634 antibody levels may be measured, without a clear understanding of the correlates of
635 protection against severe disease and the interaction of immune suppression with
636 measured immune responses, clinical inferences based on the measurement of
637 antibody levels in persons who are immunosuppressed are difficult [80]. For instance,
638 low antibody levels may not denote poor protection against severe disease; and
639 conversely, high antibody levels in a person unable to generate a commensurate
640 cellular response may not denote good protection against severe disease [80]. Our
641 review has shown high variability of anti-RBD levels between mRNA, viral vector, and
642 inactivated SARS-CoV-2 vaccines after the second dose even though anti-RBD levels
643 were quite constant after the first dose. This high variability can be due to the presence,
644 in naturally infected individuals, of neutralizing antibodies other than anti-RBD (such as
645 antibodies that recognize the N-terminal domain of the S protein) [41]. Moreover, the
646 emergence of VOC, i.e., variant strains that carry mutations potentially able to reduce
647 the neutralizing efficacy after either natural infection or vaccination has further increased
648 the risk of a diminished efficacy [81]. This is important to emphasize that males were
649 predominant in most of the included studies. However, a study reported no differences
650 by age and gender were not significant with anti-RBD median values were evaluated in
651 comparison with neutralizing titers $\geq 1:20$ or $\geq 1:80$ [41]. Besides, univariate meta-
652 regression has shown that IgG seroconversion was not correlated with the median age
653 of 25 to 60 years and CD4 > 280 cells/ μ l.

654 Our study also showed that SARS-CoV-2 vaccines tolerability was the same between
655 PLWH and HIV negatives in point of view local reactions after the first and second

656 doses of SARS-CoV-2 vaccines and systemic reactions after the 2nd dose. Local
657 reactions after the second dose of SARS-CoV-2 vaccines, on the other hand, varied
658 significantly between studies, and the results were not consistent enough due to the
659 small number of studies. Our findings showed that after the second dose of SARS-CoV-
660 2 viral vector vaccine in PLWH, local reactions were significantly reduced [16, 45].
661 Similarly, mRNA vaccine significantly reduced systemic reactions after the first SARS-
662 CoV-2 vaccines dose in PLWH [44], while HIV negative people had higher systemic
663 reactions after the first SARS-CoV-2 protein subunit vaccines dose than PLWH [46].
664 However, those results should be considered with caution because of the small sample
665 size among included studies. Concerns for adverse effects (AEs) significantly impact
666 persistent vaccine hesitancy among PLWH. Studies have shown a low level of SARS-
667 CoV-2 vaccines acceptability among PLWH compared to participants not living with
668 HIV. In China (57.2% vs 91.3%) [82, 83], Canada (65.2% vs 79.6%) [84], India (46.1%
669 vs 74.5) [83, 85], in French (71.3% vs 58.9%) [83,86]. Our findings may play a
670 substantial role to enhance COVID-19 vaccination among PLWH as fears of severe side
671 effects are a major concern in this group population [86].

672 According to our knowledge, this is the first systematic review and meta-analysis to
673 investigate the safety, tolerability, and efficacy of SARS-CoV-2 vaccines in HIV-infected
674 patients. Little research has been conducted on this topic because PLWH are a unique
675 population due to the severity and mortality rates of COVID-19. The review strength is
676 the fact that the sensitivity analysis, the overall estimate of RR of IgG seroconversion,
677 IgG antibodies levels, neutralizing antibodies response, local and systemic reactions
678 after the first and second doses of SARS-CoV-2 vaccines was robust and was

679 unaffected by a single study. However, the vaccine efficacy was influenced by a single
680 large sample size study [62].

681 Publication was not well controlled with Egger's linear regression test ($t = -3.53$ and $p =$
682 0.004) and Begg and Mazumdar's rank correlation test (Z value for Kendall's tau = -1.53
683 and $p = 0.112$) for IgG seroconversion after the second dose of SARS-CoV-2 vaccines
684 and Egger's linear regression test ($t = -3.37$ and $p = 0.007$) and Begg and Mazumdar's
685 rank correlation test (Z value for Kendall's tau = 0.85 and $p = 0.393$) for IgG antibodies
686 level after the second dose of SARS-CoV-2 vaccines. However, the review finding is
687 limited by the nature of included studies. Most studies included had small sample sizes,
688 and long-term SARS-CoV-2 IgG seroconversion, level, neutralizing antibodies, and
689 vaccine efficacy was not assessed. Larger studies will be needed to confirm and extend
690 the findings, particularly in the case of IgG antibodies level after the second dose of
691 SARS-CoV-2 vaccination in PLWH. CD4 and CD8 counts should be prioritized, as
692 SARS-CoV-2 vaccine immune responses are dependent on CD4 counts in PLWH.
693 Further research into suppressed versus non-suppressed HIV viral load is also required.
694 In the same line, more research on PLWH who are not receiving antiretroviral therapy
695 and/or have low CD4+ T-cell counts is required.

696 Besides, further consideration is that persistent infection in severely
697 immunocompromised PLWH (CD4 count < 200 cells/ μ L) may allow the emergence of
698 variant strains of SARS-CoV-2 (variants of concerns) with the potential to escape
699 immune responses [22]. This is critical for determining the efficacy of SARS-CoV-2
700 vaccines in this population. However, due to the small sample size and omission of this
701 group in various studies, the review was unable to highlight this. Adenovirus vaccine

702 vectors and HIV acquisition risk are also highlighted. Even though this outcome was
703 included in the study protocol [24], we did find studies related to it. According to
704 preliminary research, adenovirus type 5 (Ad5) immune complexes activate the dendritic
705 cell–T cell axis, which may enhance HIV-1 replication in CD4 T cells [87, 88].
706 Additionally, Ad5-specific CD4 T cells may be more susceptible to HIV infection [88, 89].
707 A participant-level meta-analysis of six randomized trials in which 224 participants
708 received recombinant adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines
709 and 179 participants received a placebo revealed an increased risk of HIV-1 infection by
710 the vaccine overall follow-up time, but no evidence of an increased risk of HIV-1
711 infection by DNA/rAd5 [90]. Due to the small sample size of most of the included trials,
712 vaccination with a rAd5 vector increased mucosal T cell activation, which remains a
713 central hypothesis to explain the potential enhancement of HIV acquisition in SARS-
714 CoV-2 vaccines based on the rAd5 vector. In the future, large efficacy trials of such
715 vaccines will be required.

716 Other study limitations were some data were taken from interim reports and the
717 supplementary data provided with them. These documents had limited information in
718 the summarized format and the individual patient data was not available, thus there is a
719 possibility to miss some important aspects. The main limitations to this analysis are
720 related with the intrinsic weaknesses of the included studies as shown in the risk of bias
721 assessment (**Supplemental materials Table 2 & 3**). However, the results showed
722 almost perfect inconsistency, indirectness, and imprecision.

723
724 **5. Conclusion**

725 According to our findings, PLWH had lower immunogenicity and antigenicity than HIV-
726 negative people after the second dose of SARS-CoV-2 vaccines. However, the
727 reactogenicity was the same after the first and second doses of SARS-CoV-2 vaccines.
728 The antigenicity was lower among PLWH with CD4<500 cells/ μ l. In contrast, the
729 immunogenicity was not different between PLWH with CD4<500 vs \geq 500 cells/ μ l as well
730 as CD4 count <350 vs \geq 350 cells/ μ l. In the same line, immunogenicity among PLWH
731 with CD4 count <200 cells/ μ l should be considered in the context of a small sample
732 size.

733 SARS-CoV-2 vaccines tolerability after the first and second dose was not different
734 between PLWH and HIV negatives. However, systemic reactions after the first and
735 second doses of SARS-CoV-2 vaccines varied between studies depending on the type
736 of vaccine. Protein subunit vaccine reported a lower risk of systemic reactions after the
737 first SARS-CoV-2 vaccine among PLWH. In the same line, both mRNA and viral vector
738 vaccines reported a lower risk of systemic reaction among PLWH.

739 Based on the above, we recommend an additional dose of SARS-CoV-2 vaccination to
740 PLWH with CD4 count \geq 200 cells/ μ l, low HIV viral loads, and on ART.

741 Our findings should be interpreted considering several study limitations, including the
742 study's small sample size and lack of long-term assessment of SARS-CoV-2
743 immunogenicity as an ideal vaccine that should provide rapid, multifaceted, long-term
744 protection. Large-scale prospective studies, including long-term antibody monitoring,
745 are required in the future for PLWH. Furthermore, more research should be conducted
746 to determine whether giving a third primary dose to PLWH with a CD4 count < 200

747 cells/l is unlikely to result in significant harms or disadvantages but may offer the
748 possibility of benefit.

749 **6. Abbreviations**

750 ACE2: angiotensin-converting enzyme 2; ART: Antiretroviral therapy; AU: BAU: BHIVA:
751 British HIV Association; CD4+ T: CD8+ T: COVID-19: coronavirus disease 2019; DNA:
752 Deoxyribonucleic acid; ELISA: enzyme-linked immunosorbent assay; FDA: Food and
753 Drug Administration; GAVI: Global Alliance for Vaccines and Immunisation GRADE:
754 Grading of Recommendations, Assessment, Development, and Evaluation; HAART:
755 highly active antiretroviral therapy; HIV: Human Immunodeficiency virus; IgG
756 immunoglobulin G; mRNA: messenger ribonucleic acid; rAd5: recombinant adenovirus
757 type 5; RBD: SARS-CoV-2 Spike Protein; ROBIN-1: PLWH: people living with HIV;
758 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses;
759 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VOC: variant(s) of
760 concern; WHO: World Health Organization

761 **7. Footnotes**

762 **Authors' contributions:** The project was initiated by JLT and PSN. JLT registered the
763 review into Prospero and conducted an electronic search of various databases. The
764 data extraction and risk of bias assessment were carried out by JLT and LMM in
765 collaboration with PSN. JLT carried out a statistical analysis. JLT wrote the manuscript
766 with the help of PSN and AM. The manuscript was reviewed and edited by JLT, PSN,
767 LMM, and AM. The final version of the manuscript was approved by all authors.

768 **Funding:** The authors have not declared a specific grant from any funding agency in
769 the public, commercial, or not-for-profit sectors for this research.

770 **Competing interests:** None declared.

771 **Availability of data and materials:** All relevant data for the study are included in the
772 article or are available as supplemental materials.

773 **Ethics approval and consent to participate:** Not applicable.

774 **Consent for publication:** Not applicable.

775 **8. References**

776 1. UNAIDS. Global HIV & AIDS statistics — Fact sheet, 2021.

777 <https://www.unaids.org/en/resources/fact-sheet>

778 2. Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR
779 Mayala BK, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000
780 and 2017. *Nature* 2019, 570(7760), pp.189-193.

781 3. Clinical features and prognostic factors of COVID-19 in people living with HIV
782 hospitalized with suspected or confirmed SARS-CoV-2 infection, 2021.

783 <https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1>

784 4. Bertagnolio S et al. Clinical characteristics and prognostic factors in people living
785 with HIV hospitalized with COVID-19: Findings from the WHO Global Clinical
786 Platform. 11th IAS Conference on HIV Science, abstract PEBLB20, 2021.

787 <https://theprogramme.ias2021.org/Abstract/Abstract/2498>

- 788 5. Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, et al. Epidemiology and
789 outcomes of COVID-19 in HIV-infected individuals: a systematic review and
790 meta-analysis. *Scientific Reports* 2021, 11(1): 1-12.
- 791 6. Deeks SG and Phillips AN. HIV infection, antiretroviral treatment, ageing, and
792 non-AIDS-related morbidity. *BMJ* 2009; 338: a3172.
- 793 7. Alrubayyi A, Gea-Mallorquí E, Touizer E, Hameiri-Bowen D, et al.
794 Characterization of humoral and SARS-CoV-2 specific T cell responses in
795 people living with HIV. *bioRxiv* 2021.
796 [https://www.biorxiv.org/content/biorxiv/early/2021/02/16/2021.02.15.431215.full.p](https://www.biorxiv.org/content/biorxiv/early/2021/02/16/2021.02.15.431215.full.pdf)
797 [df](https://www.biorxiv.org/content/biorxiv/early/2021/02/16/2021.02.15.431215.full.pdf)
- 798 8. Moir S and Fauci AS (2017), B-cell responses to HIV infection. *Immunol Rev*
799 2017; 275 (1): 33-48.
- 800 9. Pallikkuth S, et al. Impaired peripheral blood T-follicular helper cell function in
801 HIV-infected nonresponders to the 2009 H1N1/09 vaccine. *Blood* 2012; 120 (5):
802 985-93.
- 803 10. Hoffmann M, Pantazis N, Martin GE, et al. Exhaustion of Activated CD8 T Cells
804 Predicts Disease Progression in Primary HIV-1 Infection. *PLoS Pathog* 2016; 12:
805 e1005661.
- 806 11. Parmigiani A, Alcaide ML, Freguja R, Pallikkuth S, Frasca D, Fischl MA, Pahwa
807 S. Impaired antibody response to influenza vaccine in HIV-infected and
808 uninfected aging women is associated with immune activation and inflammation.
809 *PLoS One*. 2013;8(11): e79816.

- 810 12. Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, Gandhi M,
811 Brown LB. SARS-CoV-2 seroprevalence, and IgG concentration and
812 pseudovirus neutralising antibody titres after infection, compared by HIV status:
813 a matched case-control observational study. *Lancet HIV*. 2021;8(6): e334-e341.
- 814 13. Choi EM. COVID-19 vaccines for low- and middle-income countries. *Trans R*
815 *Soc Trop Med Hyg*. 2021;115(5):447-456.
- 816 14. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of 678
817 Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med* 2015;
818 373: 795–807.
- 819 15. SPARTAC Trial Investigators, Fidler S, Porter K, et al. Short-course antiretroviral
820 681 therapy in primary HIV infection. *N Engl J Med* 2013; 368: 207–17.
- 821 16. Frater J, Ewer K, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and
822 immunogenicity of the ChAdox1 nCoV-19 (AZD1222) vaccine against SARS-
823 CoV-2 in HIV infection, 2021.
824 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3829931
- 825 17. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity, and mortality
826 among patients with advanced human immunodeficiency virus infection. HIV
827 Outpatient Study Investigators. *N Engl J Med* 1998; 338: 853–60.
- 828 18. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression
829 on HIV691 specific CD8+ T cells leads to reversible immune dysfunction. *Nat*
830 *Med* 2006; 12: 1198-202
- 831 19. Paiardini M and Müller-Trutwin M. HIV-associated chronic immune activation.
832 *Immunol Rev* 2013; 254: 78–101.

- 833 20. Riou C, du Bruyn E, Stek C, Daroowala R, Goliath RT, Abrahams F, Said-Hartley
834 Q, Allwood BW, Hsiao NY, Wilkinson KA, Arlehamn CSL, Sette A, Wasserman
835 S, Wilkinson RJ; HIATUS consortium. Relationship of SARS-CoV-2-specific CD4
836 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.
837 J Clin Invest. 2021;131(12): e149125.
- 838 21. WHO. Coronavirus disease (COVID-19): COVID-19 vaccines and people living
839 with HIV, 2021. [https://www.who.int/news-room/q-a-detail/coronavirus-disease-](https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-covid-19-vaccines-and-people-living-with-hiv)
840 [\(covid-19\)-covid-19-vaccines-and-people-living-with-hiv](https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-covid-19-vaccines-and-people-living-with-hiv)
- 841 22. BHIVA. Recommendations from the Joint Committee on Vaccination and
842 Immunisation (JCVI) on a third COVID vaccine dose. Guidance for People Living
843 with HIV
- 844 23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. Updating
845 guidance for reporting systematic reviews: development of the PRISMA 2020
846 statement. Journal of Clinical Epidemiology 2021; 134: 103-112.
- 847 24. Nyasulu PS, Tamuzi JL, Ayele B. A systematic review and meta-analysis of
848 COVID-19 vaccines safety, tolerability and efficacy among HIV-infected patients.
849 PROSPERO 2021 CRD42021228863.
850 https://www.crd.york.ac.uk/prospERO/display_record.php?ID=CRD42021228863
- 851 25. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
852 2012;22(3):276-82.
- 853 26. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J,
854 Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane

- 855 Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk
856 of bias in randomised trials. *BMJ*. 2011;343: d5928.
- 857 27. Thomson H, Craig P, Hilton-Boon M, Campbell M, Katikireddi SV. Applying the
858 ROBINS-I tool to natural experiments: an example from public health. *Syst Rev*.
859 2018;7(1):15.
- 860 28. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-
861 CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *NPJ*
862 *Vaccines*. 2021;6(1):28.
- 863 29. Negahdaripour M. COVID-19 Vaccine Global Access Is an Urgency. *Iran. J.*
864 *Med. Sci*. 2021;46(2):79–80.
- 865 30. Negahdaripour M. Structural vaccinology considerations for in silico designing of
866 a multi-epitope vaccine. *Infect. Genet. Evol*. 2018; 58:96–109.
- 867 31. He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, Xu M, Liang Z. COVID-19
868 Vaccines: Current Understanding on Immunogenicity, Safety, and Further
869 Considerations. *Front Immunol*. 2021; 12:669339.
- 870 32. Keech C. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein
871 Nanoparticle Vaccine. *N. Engl. J. Med*. 2020;383(24):2320–2332.
- 872 33. Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes
873 among US patients with cancer and COVID-19 infection. *JAMA Oncol*.
874 2021;7(2):220–227.
- 875 34. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B,
876 Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-

- 877 binding domain vaccine for severe acute respiratory syndrome. *Expert Rev*
878 *Vaccines*. 2012;11(12):1405-13.
- 879 35. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the
880 development of SARS-CoV-2 vaccines. *Int J Biol Sci*. 2021; 17(1):8-19.
- 881 36. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon
882 M, Meade P, Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S,
883 Simon V, Aberg J, Reich DL, Krammer F, Cordon-Cardo C. Robust neutralizing
884 antibodies to SARS-CoV-2 infection persist for months. *Science*.
885 2020;370(6521):1227-1230.
- 886 37. Dogan M, Kozhaya L, Placek L, Gunter C, Yigit M, Hardy R, Plassmeyer M,
887 Coatney P, Lillard K, Bukhari Z, Kleinberg M, Hayes C, Arditi M, Klapper E,
888 Merin N, Liang BT, Gupta R, Alpan O, Unutmaz D. SARS-CoV-2 specific
889 antibody and neutralization assays reveal the wide range of the humoral immune
890 response to virus. *Commun Biol*. 2021;4(1):129.
- 891 38. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager
892 (RevMan) [Computer program] Version Version 5.3. Copenhagen: The Nordic
893 Cochrane Centre, The Cochrane Collaboration; 2014.
- 894 39. ProMeta 3 [Computer program] <https://idostatistics.com/prometa-3-available/>
- 895 40. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A; Depression Screening
896 Data (DEPRESSD) Collaboration. Estimating the sample mean and standard
897 deviation from commonly reported quantiles in meta-analysis. *Stat Methods Med*
898 *Res*. 2020:962280219889080.

- 899 41. Meschi S, Matusali G, Colavita F, Lapa D, Bordi L, Puro V, Leoni BD, Galli C,
900 Capobianchi MR, Castilletti C; INMI Covid-19 laboratory and investigation team.
901 Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine.
902 Clin Chem Lab Med. 2021;59(12):2010-2018.
- 903 42. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for
904 statistical and clinical significance in systematic reviews with meta-analytic
905 methods. BMC Med Res Methodol. 2014; 14:120.
- 906 43. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, Moe-Byrne T,
907 Higgins JP, Sowden A, Stewart G. A checklist designed to aid consistency and
908 reproducibility of GRADE assessments: development and pilot validation. Syst
909 Rev. 2014; 3:82.
- 910 44. Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L,
911 Huppert A, Mor O, Goldstein M, Sapir E, Hod T, Cohen C, Lustig Y, Rahav G.
912 Immunogenicity, and safety of the BNT162b2 mRNA Covid-19 vaccine in people
913 living with HIV-1. Clin Microbiol Infect. 2021: S1198-743X (21)00423-7.
- 914 45. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD,
915 Dheda K, Barnabas SL, Bhorat QE, Briner C, Aley PK, Bhikha S, Hermanus T,
916 Horne E, Jose A, Kgagudi P, Lambe T, Masenya M, Masilela M, Mkhize N,
917 Moultrie A, Mukendi CK, Moyo-Gwete T, Nana AJ, Nzimande A, Patel F, Rhead
918 S, Taoushanis C, Thombrayil A, van Eck S, Voysey M, Villafana TL, Vekemans
919 J, Gilbert SC, Pollard AJ, Moore PL, Kwatra G; Wits VIDA COVID team. Safety
920 and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against
921 SARS-CoV-2 in people living with and without HIV in South Africa: an interim

- 922 analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
923 Lancet HIV. 2021 Aug 17: S2352-3018(21)00157-0.
- 924 46. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U,
925 Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N,
926 Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de
927 Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G,
928 Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose
929 A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett
930 C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM,
931 Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373
932 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med.
933 2021;384(20):1899-1909.
- 934 47. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrrière V,
935 Trottier B, Richard J, Durand M, Kaufmann D, Finzi A, Tremblay C. Covid-19
936 vaccine immunogenicity in people living with HIV-1. bioRxiv 2021.08.13.456258;
937 doi: <https://doi.org/10.1101/2021.08.13.456258>
- 938 48. Haidar G, Agha M, Lukanski A, Linstrum K, Troyan R, Bilderback A,
939 Rothenberger S, McMahon DK, Crandall M, Enick PN, Sobolewski M.
940 Immunogenicity of COVID-19 vaccination in immunocompromised patients: an
941 observational, prospective cohort study interim analysis.
942 <https://doi.org/10.1101/2021.06.28.21259576>
- 943 49. Janssen. Use of the Janssen COVID-19 Vaccine in Patients Living with Human
944 Immunodeficiency Virus (HIV), 2021. <https://www.janssenmd.com/janssen->

- 945 covid19-vaccine/special-populations/hiv/use-of-the-janssen-covid19-vaccine-in-
946 patients-living-with-human-immunodeficiency-virus-hiv
- 947 50. Moderna COVID-19 Vaccine. Vaccines and Related Biological Products Advisory
948 Committee December 17, 2020, Meeting Briefing Document – FDA.
949 <https://www.fda.gov/media/144434/download>
- 950 51. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung P, Sang Y, Duncan MC, Yaseen
951 F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S,
952 Moran-Garcia N, Young L, Ali H, Ganase B, Umvilighozo G, Omondi FH,
953 Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C,
954 Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney
955 MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M,
956 Harris M, Hull M, Brockman MA. Humoral immune responses to COVID-19
957 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
958 medRxiv [Preprint]. 2021:2021.10.03.21264320. doi:
959 10.1101/2021.10.03.21264320.
- 960 52. Zou S, Wu M, Ming F, Wu S, Guo W, Marly G, Zeng M, Sun C, Zhang J, Tang
961 W, Liang K. Immune Response and Safety to Inactivated COVID-19 Vaccine: A
962 Comparison Between People Living with HIV and HIV-naïve Individuals, 2021.
963 Available at SSRN 3901795.
- 964 53. Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, Aley PK, Ansari
965 MA, Bara A, Broadhead S, Brown A. Durability of ChAdOx1 nCov-19 (AZD1222)
966 vaccination in people living with HIV-responses to SARS-CoV-2, variants of

- 967 concern and circulating coronaviruses, 2021. Doi:
968 <https://doi.org/10.1101/2021.09.28.21264207>
- 969 54. Feng Y, Zhang Y, He Z, Huang H, Tian X, Wang G, Chen D, Ren Y, Jia L, Wang
970 W, Wu J. Immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine in
971 people living with HIV-1, 2021.
972 <https://www.medrxiv.org/content/medrxiv/early/2021/10/15/2021.09.14.21263556>
973 .full.pdf
- 974 55. Spinelli M, Peluso MJ, Lynch KL, Yun CA, Glidden DV, Henrich TJ, Deeks S,
975 Gandhi M. Post-Mrna Vaccination SARS-CoV-2 IGG Concentrations and
976 Surrogate Virus Neutralization Response Compared by HIV Status and Type of
977 Vaccine: A Matched Case-Control Observational Study, 2021. Available at
978 SSRN 3909785.
- 979 56. Netto LC, Ibrahim KY, Picone CM, da Silva Alves AP, Aniceto EV, Santiago MR,
980 Parmejani PD, Aikawa NE, Medeiros-Ribeiro AC, Pasoto SG, Yuki EF. Safety
981 and Immunogenicity of CoronaVac in People Living with HIV, 2021.
982 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3928503
- 983 57. Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F, Smith M, Ganga Y,
984 Jule Z, Reedoy K, Miya Y. Immunogenicity of the Ad26. CoV2. S vaccine in
985 people living with HIV, 2021. doi: <https://doi.org/10.1101/2021.10.08.21264519>
- 986 58. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De
987 Pascale L, Matusali G, Mariotti D, Lepri AC. Humoral and Cellular Immune
988 Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living
989 with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current

- 990 CD4 T-Lymphocyte Count, 2021.
- 991 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3929972
- 992 59. Cai SH, Liao G, Yu T, Gao Q, Zou L, Zhang H, Xu X, Chen J, Lu A, Wu Y, Li B.
- 993 Immunogenicity and Safety of Inactivated SARS-CoV-2 Vaccine in People Living
- 994 with HIV: A Cross-Sectional Study, 2021. Available at SSRN 3912536
- 995 60. Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf
- 996 G, Ramos GM, Behrens GMN. Humoral immune response following prime and
- 997 boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
- 998 HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13202.
- 999 61. Huang X, Yan Y, Su B, Xiao D, Yu M, Jin X, Duan J, Zhang X, Zheng S, Fang Y,
- 1000 Tang W. Comparing Immune Responses to Inactivated Vaccines Against SARS-
- 1001 CoV-2 Between People Living with HIV and HIV-Negative Individuals: A Cross-
- 1002 Sectional Study in China.
- 1003 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3941042
- 1004 62. Mazus A, Gushchin VA, Tsyganova EV, Ogarkova DA, Adgamov RR,
- 1005 Shcheblyakov DV, Glukhoedova NV, Zhilenkova A, Kolotii AG, Zaitsev RD,
- 1006 Logunov DY. Sputnik V Protection from COVID-19 of HIV-Infected Individuals
- 1007 Under Art. Available at SSRN 3949413. 2021 Oct 25.
- 1008 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949413
- 1009 63. Lv Z, Li Q, Feng Z, Zheng X, Yang H, Gu Q, Ying S, Qi Y, Li X, Wu R, Wu Z.
- 1010 Inactivated SARS-CoV-2 Vaccines Elicit Immunogenicity and T-cell Responses
- 1011 in People Living with HIV. International Immunopharmacology. 2021; 18:108383.

- 1012 64. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G,
1013 Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L,
1014 Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini
1015 D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K,
1016 Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S; COVAXID-
1017 collaborator group (shown separately). Safety and efficacy of the mRNA
1018 BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised
1019 patients and healthy controls in a prospective open-label clinical trial.
1020 EBioMedicine. 2021; 74:103705.
- 1021 65. Cheng SH, Lien CE, Hsieh SM, Cheng CY, Liu WD, Lo CL, Ko WC, Chen YH,
1022 Huang CT, Chang HT, Hwang SJ. Safety and Immunogenicity of SARS-CoV-2
1023 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV, 2021.
1024 <https://www.medrxiv.org/content/10.1101/2021.12.08.21267439v1.full.pdf>
- 1025 66. Noe S, Ochana N, Wiese C, Schabaz F, Von Krosigk A, Heldwein S, Rasshofer
1026 R, Wolf E, Jonsson-Oldenbuettel C. Humoral response to SARS-CoV-2 vaccines
1027 in people living with HIV. Infection. 2021:1–7.
- 1028 67. Xiao Y, Wu S, Marly G, Ming F, Wu M, et al. People Living with HIV Easily Lose
1029 Their Immune Response to SARS-CoV-2: Result from a Cohort of COVID-19
1030 Cases in Wuhan, China 2021. <http://dx.doi.org/10.2139/ssrn.3774187>
- 1031 68. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Pillai S et al. Pfizer-
1032 BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and
1033 immune response among individuals in clinical risk groups. 2021.

- 1034 <https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+pape>
1035 [r.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f](https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+pape)
- 1036 69. CDC. COVID-19 Vaccines for Moderately to Severely Immunocompromised
1037 People, 2021. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html)
1038 [ncov/vaccines/recommendations/immuno.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html)
- 1039 70. FDA. Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the
1040 Use of a Booster Dose for COVID-19 Vaccines, 2021.
1041 [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines)
1042 [update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines)
- 1043 71. Roifman CM and Vong L. COVID-19 post-vaccination recommendations in
1044 primary immunodeficiency, 2021.
1045 <https://lymphosign.com/doi/abs/10.14785/lymphosign-2021-0023>
- 1046 72. BHIVA. SARS-CoV-2 vaccine advice for adults living with HIV: British HIV
1047 Association (BHIVA) & Terrence Higgins Trust (THT) guidance, 2021.
1048 [https://www.bhiva.org/SARS-CoV-2-vaccine-advice-for-adults-living-with-HIV-](https://www.bhiva.org/SARS-CoV-2-vaccine-advice-for-adults-living-with-HIV-update)
1049 [update](https://www.bhiva.org/SARS-CoV-2-vaccine-advice-for-adults-living-with-HIV-update)
- 1050 73. WHO. Interim statement on COVID-19 vaccine booster doses, 2021.
1051 [https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-](https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses)
1052 [vaccine-booster-doses](https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses)
- 1053 74. Biggar RJ, Goedert JJ and Hoofnagle J., 1987. Accelerated loss of antibody to
1054 hepatitis B surface antigen among immunodeficient homosexual men infected
1055 with HIV. *The New England journal of medicine* 1987; 316(10): 630-631.

- 1056 75. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, Kenney T, et al. Poor
1057 immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected
1058 individuals. *Aids* 2010, 24(14): 2187-2192.
- 1059 76. Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, et al. Long-term immune
1060 responses to vaccination in HIV-infected patients: a systematic review and meta-
1061 analysis. *Clinical infectious diseases* 2014, 58(8), pp.1130-1139.
- 1062 77. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine
1063 injections augments anti-HBs response rate in HIV-infected patients. Effects on
1064 HIV-1 viral load. *Vaccine* 2000; 18: 1161–5.
- 1065 78. Gong C, Song X, Li X, Lu L, Li T. Immunological Changes after COVID-19
1066 Vaccination in an HIV-Positive Patient. *Int J Infect Dis.* 2021: S1201-
1067 9712(21)00667-6.
- 1068 79. Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D, Gori
1069 A, Bandera A. Transient increase in plasma HIV RNA after COVID-19
1070 vaccination with mRNA-1272. *Int J Infect Dis.* 2021; 113:125-126.
- 1071 80. BHIVA. UPDATE: Intensive Care Society (ICS) and British HIV Association
1072 (BHIVA) statement on considerations for critical care for people with HIV during
1073 COVID-19, 2020. [https://www.bhiva.org/updated-ICS-BHIVA-statement-on-](https://www.bhiva.org/updated-ICS-BHIVA-statement-on-considerations-for-critical-care-for-people-with-HIV-during-COVID-19)
1074 [considerations-for-critical-care-for-people-with-HIV-during-COVID-19](https://www.bhiva.org/updated-ICS-BHIVA-statement-on-considerations-for-critical-care-for-people-with-HIV-during-COVID-19)
- 1075 81. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et
1076 al. An observational cohort study on the incidence of SARS-CoV-2 infection and
1077 B.1.1.7 variant infection in healthcare workers by antibody and vaccination status

- 1078 medRxiv 2021 [Internet]. Available from: <http://medrxiv.org/content/early/>
1079 2021/03/12/2021.03.09.21253218.
- 1080 82. Huang X, Yu M, Fu G, Lan G, Li L, Yang J, Qiao Y, Zhao J, Qian HZ, Zhang X,
1081 Liu X, Jin X, Chen G, Jiang H, Tang W, Wang Z, Xu J. Willingness to Receive
1082 COVID-19 Vaccination Among People Living with HIV and AIDS in China:
1083 Nationwide Cross-sectional Online Survey. *JMIR Public Health Surveill.*
1084 2021;7(10): e31125.
- 1085 83. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic
1086 Review of Vaccine Acceptance Rates. *Vaccines (Basel)*. 2021 Feb 16;9(2):160.
1087 doi: 10.3390/vaccines9020160. PMID: 33669441; PMCID: PMC7920465.
- 1088 84. Kaida A, Brotto LA, Murray MC, Côté HC, Albert AY, Nicholson V, Gormley R,
1089 Gordon S, Booth A, Smith LW, Baaske A. Intention to receive a COVID-19
1090 vaccine by HIV status among a population-based sample of women and gender
1091 diverse individuals in British Columbia, Canada. *medRxiv*. 2021 Jan 1. doi:
1092 <https://doi.org/10.1101/2021.08.19.21262249>
- 1093 85. Ekstrand ML, Heylen E, Gandhi M, Steward WT, Pereira M, Srinivasan K.
1094 COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for
1095 Vaccination Campaigns. *J Acquir Immune Defic Syndr*. 2021;88(5):421-425.
- 1096 86. Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 Vaccine
1097 Hesitancy among French People Living with HIV. *Vaccines (Basel)*. 2021 Mar
1098 24;9(4):302.

- 1099 87. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by
1100 Ad5 immune complexes creates an improved environment for replication of HIV
1101 in T cells. *J Exp Med* 2008; 205: 2717–25.
- 1102 88. Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5
1103 vectored vaccines: a cautionary tale. *Lancet*. 2020;396(10260): e68-e69.
- 1104 89. Auclair S, Liu F, Niu Q, et al. Distinct susceptibility of HIV vaccine vector induced
1105 CD4 T cells to HIV infection. *PLoS Pathog* 2018; 14: e1006888.
- 1106 90. Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z,
1107 Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A,
1108 McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG,
1109 Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB. Effect of rAd5-
1110 Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level
1111 Meta-Analysis of Randomized Trials. *PLoS One*. 2015;10(9): e0136626.




Figure 1: Flow diagram of COVID-19 vaccines safety, tolerability, and efficacy among HIV-infected patients

Distribution of twenty-three included studies in different countries




Figure 2: Distribution of twenty-three included studies in different countries




Figure 3: Forest plot analysis of the overall risk ratio RBD antibody responses after the first dose of SARS-CoV-2 vaccines among PLWH and HIV-negative people.




Figure 4: Forest plot analysis of the overall risk ratio RBD antibody responses after the second dose of SARS-CoV-2 vaccines among PLWH and HIV-negative people.




Figure 5: Forest plot of mean difference IgG antibody level (BAU/ml) after the second dose of SARS-CoV-2 vaccines




Figure 6: Forest plot of mean difference IgG antibody level (BAU/ml) after the second of SARS-CoV-2 vaccines




Figure 7: Meta-analysis of SARS-CoV-2 vaccines effectiveness: vaccinated vs unvaccinated PLWH.




Figure 8: Meta-analysis of SARS-CoV-2 vaccines effectiveness based on CD4 count




Figure 9: Pooled results of SARS-CoV-2 vaccines neutralizing antibodies response after the second dose




Figure 10: Forest plot analysis compared the overall risk ratio of local reactions after the first dose of SARS-CoV-2 vaccines among PLWH and HIV negatives.




Figure 11: Forest plot of systemic reactions after the first dose of SARS-CoV-2 vaccines: PLWH vs HIV negative participants




Figure 12: Forest plot of local reactions between PLWH and HIV negatives after 2nd dose of SARS-CoV-2 vaccines




Figure 13: Forest plot of systemic reactions between PLWH and HIV negatives after 2nd dose SARS-CoV-2 vaccines




Figure 14: Pooled results of IgG seroconversion among PLWH based on CD4 count <500 or ≥500 cells/μL




Figure 15: Pooled results of IgG seroconversion among PLWH based on CD4 count <200 or ≥200 cells/μL





Figure 16: Pooled results of neutralizing antibodies response among PLWH (<500 vs ≥500 cells/μL)

Univariate meta-regression

Median age (years) and SARS-CoV-2 IgG antibodies level (BAU/ml)



Median CD4(cells/ μ L) and SARS-CoV-2 IgG antibodies level (BAU/ml)





Figure 17 a: Meta-regression of Median age (years) and SARS-CoV-2 IgG antibodies level (BAU/ml). Figure 17 b: Median CD4(cells/ μ L) and SARS-CoV-2 IgG antibodies level (BAU/ml)

Publication bias

Funnel plot of IgG seroconversion after the second dose of SARS-CoV-2 vaccination



Funnel plot of IgG antibodies level (BAU/ml) after the second dose of SARS-CoV-2 vaccination




Figure 18a: Funnel plot of IgG seroconversion after the second dose of SARS-CoV-2 vaccination. Figure 18b: Funnel plot of IgG antibodies level (BAU/ml) after the second dose of SARS-CoV-2 vaccination